U.S. FDA Grants BeiGene’s BRUKINSA™ (zanubrutinib) Accelerated Approval to Treat Adult Patients with Mantle Cell Lymphoma Who Received at Least One Prior Therapy

    NEXT STORY
    SELLAS Life Sciences Provides Business Update and Reports Third Quarter 2019 Financial Results
    PREV STORY
    CorMedix Inc. Reports Third Quarter 2019 Financial Results and Provides Business Update
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    World-Renowned Pioneers in Oncoplastic Surgery Featured at Upcoming Global Summit in Las Vegas, January 2020

    author_avatar
    NASDAQ Market News

    Axsome Therapeutics to Report Third Quarter 2018 Financial Results on November 9, 2018

    Axsome to host conference call and webcast on Friday, November 9, 2018 at 8:00 ...

    author_avatar
    NASDAQ Market News

    European Commission approves Roche’s Tecentriq in combination with Abraxane for people with PD-L1-positive, metastatic triple-negative breast cancer

    author_avatar
    NASDAQ Market News